Inhibition of HDAC6 With CAY10603 Ameliorates Diabetic Kidney Disease by Suppressing NLRP3 Inflammasome

by Selleckchem | Oct 22 2023

Background: Diabetic nephropathy (DN) is one of the leading causes of chronic kidney disease (CKD) worldwide, tubular injury is the driving force during the pathogenesis and progression of DN. Thus, we aim to utilize the connectivity map (CMap) with renal tubulointerstitial transcriptomic profiles of biopsy-proven DN to identify novel drugs for treating DN.

Methods: We interrogated the CMap profile with tubulointerstitial transcriptomic data from renal biopsy-proven early- and late-stage DN patients to screen potential drugs for DN. Therapeutic effects of candidate drug were assessed in Murine model of diabetic kidney disease (STZ-induced CD-1 mice), and HK-2 cells and immortalized bone marrow-derived macrophages (iBMDMs).

Results: We identified CAY10603, a specific inhibitor of histone deacetylase 6 (HDAC6), as a potential drug that could significantly reverse the altered genes in the tubulointerstitial component. In DN patients and mice, upregulation of HDAC6 was mainly observed in renal tubular cells and infiltrated macrophages surrounding the diluted tubules. In both early- and late-onset diabetic mice, daily CAY10603 administration effectively alleviated renal dysfunction and reduced macrophage infiltration, tubular injury and tubulointerstitial fibrosis. Mechanistically, CAY10603 suppressed NLRP3 activation in both HK-2 cells and iBMDMs.

Conclusion: CAY10603 exhibited therapeutic potential for DN by suppressing NLRP3 inflammasome activation in both tubular cells and macrophages.

Comments:

That's an interesting study you've summarized! It appears that the researchers aimed to identify potential drugs for treating diabetic nephropathy (DN) by utilizing the connectivity map (CMap) and analyzing tubulointerstitial transcriptomic profiles from renal biopsy-proven DN patients. Here are the key findings and methods described in the summary:

Methods:
1. Tubulointerstitial transcriptomic data from renal biopsy-proven early- and late-stage DN patients were used to interrogate the CMap profile.
2. The goal was to screen potential drugs for DN based on the analysis of the CMap data.
3. The therapeutic effects of the candidate drug were assessed in a murine model of diabetic kidney disease using STZ-induced CD-1 mice.
4. In vitro experiments were conducted using HK-2 cells (a human proximal tubular cell line) and immortalized bone marrow-derived macrophages (iBMDMs).

Results:
1. The researchers identified CAY10603, a specific inhibitor of histone deacetylase 6 (HDAC6), as a potential drug that could reverse the altered genes in the tubulointerstitial component associated with DN.
2. HDAC6 upregulation was observed in renal tubular cells and infiltrated macrophages surrounding the diluted tubules in DN patients and mice.
3. Daily administration of CAY10603 effectively alleviated renal dysfunction, reduced macrophage infiltration, tubular injury, and tubulointerstitial fibrosis in both early- and late-onset diabetic mice.
4. Mechanistically, CAY10603 suppressed NLRP3 inflammasome activation in both HK-2 cells and iBMDMs.

Conclusion: The findings suggest that CAY10603, an HDAC6 inhibitor, exhibited therapeutic potential for treating DN by suppressing NLRP3 inflammasome activation in both tubular cells and macrophages. This indicates that targeting HDAC6 and NLRP3 inflammasome signaling pathways could be a promising approach for the treatment of DN.